Key pharma stocks, including Granules India and Gland Pharma, have shown substantial recovery, with the Nifty Pharma index ...

a wholly owned subsidiary of Aurobindo Pharma, and enter into a contract manufacturing relationship. In addition to the Houston facility, the site will serve as the second FDA-registered ...

Aurobindo Pharma shares traded 1% higher on Tuesday despite a slight dip in its fourth-quarter profits to ₹903 crore.

An FDA inspection of an Aurobindo Pharma manufacturing facility last fall ... Sandoz in the U.S. as well as three manufacturing sites. That deal was announced in 2018 but has been repeatedly ...

India’s Aurobindo Pharma has acquired four biosimilar products ... it would build a second sterile injectables plant on a site in New Jersey, partly in response to tax talk from President ...

Aurobindo Pharma USA Inc., the New Jersey-based unit for an Indian generic drug developer by the same name, has committed to establishing a new national headquarters for research and development ...

The new site has been completed with an investment ... Muralidharan, President, European Operations at Aurobindo Pharma, said: "We are delighted to be reinforcing our commitment to the Auvergne ...

Aurobindo Pharma Ltd. is an integrated pharmaceutical company that delivers innovative solutions. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients.

WASHINGTON (KDKA) - Two lots of blood medication are being recalled. Aurobindo Pharma USA is recalling some Quinapril and Hydrochlorothiazide tablets because they contain too high levels of ...

Aurobindo Pharma (NS:ARBN) has outperformed expectations in the fourth quarter of FY24, with both sales and EBITDA showing significant year-over-year growth. Sales increased by 17%, while EBITDA ...